Presentation( PDF format / 607KB )

Business Results

First Six Months of the

Fiscal Year Ending March 31, 2022

Sysmex Corporation

Hisashi Ietsugu, Chairman and CEO

November 11, 2021

Index

1. Business Results, First Six Months of the Fiscal Year Ending March 31, 2022
2. Financial Forecast for the
   Fiscal Year Ending March 31, 2022

(Appendix)

・Q2 Business Results

・Results by Geographic Region

The Sysmex Group adopted International Financial Reporting Standards (IFRS) in the fiscal year ended March 31, 2017. Figures are disclosed in compliance with IFRS.

Forward-Looking Statements

This material contains forward-looking statements about Sysmex Corporation and its Group companies (the Sysmex Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.

Executive Summary

First-Half Results

・Increases in net sales and operating profit

(+27.8% YoY for net sales, +68.5% YoY for operating profit)

• Testing demand has continued to recover since the second half of the previous fiscal year, and sales increased in direct sales areas. These factors pushed up sales, mainly of reagents, leading to higher sales across all regions and in all fields.
• Operating profit rose due to higher gross profit, stemming from higher net sales, and an improved cost of sales ratio, reflecting the product mix.

Full-Year Forecast

・Revised upward our forecast for the fiscal year ending March 31, 2022

• Net sales and operating profit expected to reach full-yearforecast levels announced at the beginning of the fiscal year
• We have changed our assumed exchange rate for the second half, taking into consideration actual exchange rates for the first half and the trend toward yen depreciation.

3

1.	Business Results, First Six Months of
	the Fiscal Year Ending March 31, 2022

Financial Highlights (Year-on-Year)

(Billions of yen)

168.7

	136.1	142.9
131.1	132.0

33.7

28.0 28.5 27.8

20.0

22.2

19.1	19.4	17.5

12.6

2018	2019	2020	2021	2022
(First six months of years to March 31)

Net sales

Operating profit

Profit attributable to owners of the parent

	First six months of	First six months of
	fiscal year ending	fiscal year ended
	March 31, 2022	March 31, 2021
1USD	¥109.8	¥106.9
1EUR	¥130.9	¥121.3
1CNY	¥17.0	¥15.3

	First six months of	First six months of
	fiscal year ending	fiscal year ended	YoY (Previous
	March 31, 2022	March 31, 2021
(Billions of yen)	period = 100%)
	Results	Ratio	Results	Ratio
Net sales	168.7	100%	132.0	100%	127.8%
Cost of sales	78.9	46.8%	64.7	49.1%	121.8%
SG&A expenses	44.0	26.1%	38.0	28.8%	115.7%
R&D expenses	11.6	6.9%	9.7	7.4%	119.1%
Other income	(0.4)	(0.3)%	0.5	0.4%	-
(expenses)
Operating profit	33.7	20.0%	20.0	15.1%	168.5%
Profit attributable to	22.2	13.2%	12.6	9.6%	175.8%
owners of the parent

• Net sales: As expected, we experienced a recovery in testing demand (which had decreased in the previous year), which lifted reagent sales, and the impact of exchange rates (yen depreciation). As a result, net sales rose.
• Operating profit: SG&A expenses increased. Even so, operating profit grew thanks to

higher sales, which pushed up gross profit and improved the cost of sales ratio.

Exchange rate fluctuations raised net sales ¥9.51 billion and increased operating profit ¥3.17 billion. At the exchange rates prevailing one year earlier, net sales would have been up 20.6% year on year, and operating profit up 52.7%.

• Profit attributable to owners of the parent: Profit was up due to higher operating profit and an improvement in exchange gains and losses.

Exchange gains (losses): Loss of ¥0.01 billion (loss of ¥0.70 billion in same period of
previous fiscal year)	5